THE BRIGHAM AND WOMEN'S HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENTAssignment and Assumption Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement ("Agreement") is made as of the second day of March, 2012 ("Effective Date"), by and between Alopexx Vaccine, LLC, a limited liability company, having a principal place of business at [***] ("Company") and The Brigham and Women's Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 ("Hospital"), each referred to herein individually as a "Party" and collectively as the "Parties".
THE BRIGHAM AND WOMEN’S HOSPITAL, INC. EXCLUSIVE LICENSE AGREEMENTLicense Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“AGREEMENT”) is made as of the 4th day of December, 2007 (“EFFECTIVE DATE”), between Alopexx Pharmaceuticals, LLC, a Delaware limited liability company, having a principal place of business at [***](“COMPANY”) and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, MA 02115 (“HOSPITAL”), each referred to herein individually as a “PARTY” and collectively as the “PARTIES”.
AMENDMENT No. 5 to the EXCLUSIVE PATENT LICENSE AGREEMENT BWH Case No. [***], [***], [***] BWH Agreement No. [***]Patent License Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 5 to the Exclusive Patent License Agreement (“Amendment No. 5”) is effective as of February 2, 2022 (“Amendment No. 5 Effective Date”), by and between The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”) and Alopexx, Inc., a Delaware corporation, having a principal place of business at [***] (“Company”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the License Agreement (as defined below).
AMENDMENT No. 2 to the EXCLUSIVE PATENT LICENSE AGREEMENT BWH Case No. [***], [***], [***], [***] BWH Agreement No. [***]Patent License Agreement • March 7th, 2022 • Alopexx, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the Exclusive Patent License Agreement (“Amendment No. 2”) is effective as of February 2, 2022 (“Amendment No. 2 Effective Date”), by and between The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”) and Alopexx, Inc., a Delaware corporation, having a principal place of business at 186 Alewife Brook Pkwy #1068 Cambridge, MA 02138 (“Company”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the License Agreement (as defined below).
